A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Sickle Cell Disease

In brief

The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.

Key facts

Study ID
NCT06924970
Run by
Agios Pharmaceuticals, Inc.
People needed
59
Starts
2025-05-01
Expected to finish
2027-05-01
Last updated by the study team
2026-05-29

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.